BECTON Reports Profitable Third Quarter Results for FY2023
August 28, 2023
☀️Earnings Overview
BECTON ($NYSE:BDX) has reported its earnings for the third quarter of FY2023, ending June 30th 2023. Total revenue hit USD 4878.0 million, a 5.1% increase compared to the same period in the year prior. Net income for the quarter has grown 13.1% from last year, with a total of USD 407.0 million.
Stock Price
On Thursday, BECTON reported their third quarter results for FY2023, and it was a profitable one. The stock market reacted favorably to the news, with BECTON stock opening at $275.3 and closing at $268.7. This marks a slight decline of 2.7% from the previous closing price of $276.2. This signifies that investors are cautiously optimistic about the company’s earnings prospects for the coming quarters.
Overall, BECTON has had a very successful third quarter, and it is likely that their performance will continue in the upcoming quarters. With their solid financial results, BECTON is well-positioned to continue to grow and expand in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Becton. More…
| Total Revenues | Net Income | Net Margin |
| 19.05k | 1.58k | 10.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Becton. More…
| Operations | Investing | Financing |
| 2.64k | -2.86k | -1.51k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Becton. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 53.02k | 27.08k | 89.41 |
Key Ratios Snapshot
Some of the financial key ratios for Becton are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.0% | 12.2% | 11.8% |
| FCF Margin | ROE | ROA |
| 9.1% | 5.4% | 2.6% |
Analysis
At GoodWhale, we have performed an extensive analysis of BECTON‘s financials and are pleased to report that they have been rated a medium risk investment in terms of financial and business aspects. While this may seem like a common rating, it is an important one to take into account when making investment decisions. Further, when we inspected BECTON’s income sheet and balance sheet, we discovered two risk warnings that require attention. To get more information on these risk warnings and how they could affect your investments, we highly recommend that you register with us. With our analysis and guidance, you can make more informed decisions when it comes to investing in BECTON. More…
Peers
Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, instruments, and supplies. The company operates in three segments: BD Medical, BD Biosciences, and BD Diagnostics. It offers a wide range of products, including syringes, needles, catheters, blood collection devices, IV administration and infusion products, safety products, and sharps disposal systems. The company competes with Penumbra Inc, Teleflex Inc, SheerVision Inc, and other medical technology companies.
– Penumbra Inc ($NYSE:PEN)
Founded in 2002, Umbra is a leading global provider of shading and decorative products. The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods. Headquartered in Toronto, Canada, Umbra employs over 1,200 people worldwide.
Umbra’s market cap is 7.01B as of 2022. The company’s Return on Equity is -2.31%.
The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods.
– Teleflex Inc ($NYSE:TFX)
Teleflex Incorporated is a diversified global provider of medical technologies designed to improve the health and quality of people’s lives. The Company provides solutions for critical care, anesthesia, surgical, urology and emergency medicine.
– SheerVision Inc ($OTCPK:SVSO)
SheerVision Inc is a US-based company that manufactures and sells ophthalmic surgical instruments and devices. The company has a market cap of 140.32k as of 2022 and a Return on Equity of -70.28%. SheerVision’s products are used by eye surgeons to correct vision problems such as nearsightedness, farsightedness, and astigmatism. The company’s products are sold through a network of distributors and retailers worldwide.
Summary
BECTON has produced very positive results for the third quarter of FY2023, with total revenues increasing by 5.1% and net income rising by 13.1%. This indicates strong growth and is an attractive sign for investors, especially given the current economic climate. Investors should consider BECTON a safe choice due to its robust financials and may find it a profitable long-term investment.
BECTON offers attractive dividends to shareholders and offers good value of return. The company’s outlook looks positive and could present further opportunities to investors.
Related Posts
Recent Posts
